Compare Stocks: PHMMF, XENE, KNSA, and PTCT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KNSA Kiniksa Pharmaceuticals International	$79.03 +0.7%	$67.35	$32.89 ▼ $82.94	$6.12B	0.05	717,864 shs	270,111 shs
PHMMF Pharma Mar	$87.58	$84.75	$77.41 ▼ $110.40	$1.58B	0.7	28 shs	30 shs
PTCT PTC Therapeutics	$69.82 -1.0%	$77.62	$48.28 ▼ $90.87	$5.89B	0.56	1.24 million shs	674,738 shs
XENE Xenon Pharmaceuticals	$60.77 +1.7%	$62.32	$35.60 ▼ $72.66	$5.77B	0.62	631,514 shs	783,719 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KNSA Kiniksa Pharmaceuticals International	+0.71%	+2.97%	+26.57%	+48.44%	+137.97%
PHMMF Pharma Mar	0.00%	0.00%	+1.73%	-17.75%	-9.43%
PTCT PTC Therapeutics	-0.99%	-2.62%	-10.94%	+1.47%	+42.93%
XENE Xenon Pharmaceuticals	+1.74%	-2.53%	-8.17%	+12.18%	+61.45%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KNSA Kiniksa Pharmaceuticals International	$79.03 +0.7%	$67.35	$32.89 ▼ $82.94	$6.12B	0.05	717,864 shs	270,111 shs
PHMMF Pharma Mar	$87.58	$84.75	$77.41 ▼ $110.40	$1.58B	0.7	28 shs	30 shs
PTCT PTC Therapeutics	$69.82 -1.0%	$77.62	$48.28 ▼ $90.87	$5.89B	0.56	1.24 million shs	674,738 shs
XENE Xenon Pharmaceuticals	$60.77 +1.7%	$62.32	$35.60 ▼ $72.66	$5.77B	0.62	631,514 shs	783,719 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KNSA Kiniksa Pharmaceuticals International	+0.71%	+2.97%	+26.57%	+48.44%	+137.97%
PHMMF Pharma Mar	0.00%	0.00%	+1.73%	-17.75%	-9.43%
PTCT PTC Therapeutics	-0.99%	-2.62%	-10.94%	+1.47%	+42.93%
XENE Xenon Pharmaceuticals	+1.74%	-2.53%	-8.17%	+12.18%	+61.45%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KNSA Kiniksa Pharmaceuticals International	2.80	Moderate Buy	$87.38	10.56% Upside
PHMMF Pharma Mar	3.00	Buy	N/A	N/A
PTCT PTC Therapeutics	2.64	Moderate Buy	$98.55	41.14% Upside
XENE Xenon Pharmaceuticals	3.00	Buy	$77.13	26.93% Upside

Current Analyst Ratings Breakdown

Latest PHMMF, XENE, KNSA, and PTCT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/17/2026	PTCT PTC Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
8/14/2026	PTCT PTC Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$120.00 ➝ $122.00
8/13/2026	KNSA Kiniksa Pharmaceuticals International	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B-) ➝ Hold (C+)
8/13/2026	PTCT PTC Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$106.00 ➝ $109.00
8/10/2026	XENE Xenon Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$74.00
8/7/2026	XENE Xenon Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$82.00 ➝ $81.00
8/6/2026	PTCT PTC Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/31/2026	PTCT PTC Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
7/31/2026	PTCT PTC Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$93.00 ➝ $104.00
7/31/2026	PTCT PTC Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$93.00 ➝ $106.00
7/30/2026	KNSA Kiniksa Pharmaceuticals International	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 8/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KNSA Kiniksa Pharmaceuticals International	$677.56M	9.10	$0.80 per share	98.86	$8.38 per share	9.43
PHMMF Pharma Mar	$250.42M	6.30	$0.41 per share	211.45	N/A	∞
PTCT PTC Therapeutics	$1.73B	3.37	$8.69 per share	8.03	($1.98) per share	-35.26
XENE Xenon Pharmaceuticals	$7.50M	783.28	N/A	N/A	$12.85 per share	4.73

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KNSA Kiniksa Pharmaceuticals International	$59.01M	$0.97	81.47	38.18	N/A	9.59%	13.65%	10.09%	10/27/2026 (Estimated)
PHMMF Pharma Mar	$84.84M	N/A	N/A	40.92	N/A	N/A	N/A	N/A	10/29/2026 (Estimated)
PTCT PTC Therapeutics	$682.64M	-$0.58	N/A	32.78	2.18	-3.80%	-362.45%	-1.32%	11/3/2026 (Estimated)
XENE Xenon Pharmaceuticals	-$345.91M	-$4.74	N/A	N/A	N/A	N/A	-43.98%	-41.72%	11/2/2026 (Estimated)

Latest PHMMF, XENE, KNSA, and PTCT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	XENE Xenon Pharmaceuticals	-$1.16	-$1.11	+$0.05	-$1.11	$1.67 million	N/A
7/30/2026	Q2 2026	PTCT PTC Therapeutics	$0.2363	$0.92	+$0.6837	$0.92	$298.63 million	$360.52 million
7/28/2026	Q2 2026	KNSA Kiniksa Pharmaceuticals International	$0.2995	$0.30	+$0.0005	$0.30	$226.49 million	$243.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
KNSA Kiniksa Pharmaceuticals International	N/A	N/A	N/A	N/A	N/A
PHMMF Pharma Mar	N/A	N/A	N/A	N/A	N/A
PTCT PTC Therapeutics	N/A	N/A	N/A	N/A	N/A
XENE Xenon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KNSA Kiniksa Pharmaceuticals International	N/A	3.90	3.49
PHMMF Pharma Mar	0.14	3.02	2.44
PTCT PTC Therapeutics	N/A	3.39	3.28
XENE Xenon Pharmaceuticals	N/A	21.01	21.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KNSA Kiniksa Pharmaceuticals International	53.95%
PHMMF Pharma Mar	N/A
PTCT PTC Therapeutics	N/A
XENE Xenon Pharmaceuticals	95.45%

Insider Ownership

Company	Insider Ownership
KNSA Kiniksa Pharmaceuticals International	51.98%
PHMMF Pharma Mar	1.88%
PTCT PTC Therapeutics	5.30%
XENE Xenon Pharmaceuticals	2.91%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KNSA Kiniksa Pharmaceuticals International	220	78.02 million	37.47 million	Optionable
PHMMF Pharma Mar	509	18.00 million	17.66 million	Not Optionable
PTCT PTC Therapeutics	1,410	83.46 million	79.04 million	Optionable
XENE Xenon Pharmaceuticals	210	96.67 million	93.85 million	Optionable

PHMMF, XENE, KNSA, and PTCT Headlines

Recent News About These Companies

Bank of America Corp DE Increases Stock Holdings in Xenon Pharmaceuticals Inc. $XENE

August 21 at 3:12 AM | marketbeat.com

Xenon Pharmaceuticals Inc

August 18, 2026 | money.usnews.com

TimesSquare Capital Management LLC Purchases Shares of 451,593 Xenon Pharmaceuticals Inc. $XENE

August 18, 2026 | marketbeat.com

Walleye Capital LLC Buys New Position in Xenon Pharmaceuticals Inc. $XENE

August 15, 2026 | marketbeat.com

Steven Gannon Sells 10,000 Shares of Xenon Pharmaceuticals (NASDAQ:XENE) Stock

August 14, 2026 | insidertrades.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Rating of "Buy" by Brokerages

August 14, 2026 | marketbeat.com

Xenon Pharmaceuticals (XENE) Q2 2026 Earnings Call Transcript

August 13, 2026 | finance.yahoo.com

Xenon Pharmaceuticals (NASDAQ:XENE) Director Sells 10,000 Shares of Stock

August 13, 2026 | marketbeat.com

Q3 EPS Forecast for Xenon Pharmaceuticals Boosted by Analyst

August 13, 2026 | americanbankingnews.com

Xenon Pharmaceuticals: Strong Buy On Azetukalner NDA And MDD Expansion Opportunity

August 11, 2026 | seekingalpha.com

HC Wainwright Issues Positive Outlook for XENE Earnings

August 11, 2026 | marketbeat.com

Brokers Issue Forecasts for XENE Q1 Earnings

August 10, 2026 | marketbeat.com

Quantinno Capital Management LP Purchases 30,816 Shares of Xenon Pharmaceuticals Inc. $XENE

August 9, 2026 | marketbeat.com

Xenon anticipates AZK NDA submission later this quarter, while funding operations into 2029

August 7, 2026 | seekingalpha.com

Xenon Pharmaceuticals' Azetukalner NDA Filing Remains on Track After FDA Meeting, RBC Says

August 7, 2026 | finance.yahoo.com

Xenon Pharmaceuticals Q2 Earnings Call Highlights

August 7, 2026 | marketbeat.com

XENE's Q2 Loss Narrower Than Expected, Sales Nil, Pipeline in Focus

August 7, 2026 | zacks.com

California State Teachers Retirement System Buys 36,183 Shares of Xenon Pharmaceuticals Inc. $XENE

August 7, 2026 | marketbeat.com

Xenon Pharmaceuticals Inc. (XENE) Q2 2026 Earnings Call Transcript

August 7, 2026 | seekingalpha.com

Xenon Pharmaceuticals Q2 Loss Widens

August 7, 2026 | finance.yahoo.com

Xenon Pharmaceuticals (NASDAQ:XENE) Announces Quarterly Earnings Results

August 6, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHMMF, XENE, KNSA, and PTCT Company Descriptions

Kiniksa Pharmaceuticals International NASDAQ:KNSA

$79.03 +0.56 (+0.71%)

As of 08/21/2026 04:00 PM Eastern

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Pharma Mar OTCMKTS:PHMMF

$87.58 0.00 (0.00%)

As of 08/20/2026

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer. The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.

PTC Therapeutics NASDAQ:PTCT

$69.82 -0.70 (-0.99%)

As of 08/21/2026 04:00 PM Eastern

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Xenon Pharmaceuticals NASDAQ:XENE

$60.77 +1.04 (+1.74%)

As of 08/21/2026 04:00 PM Eastern

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PHMMF, XENE, KNSA, and PTCT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PHMMF, XENE, KNSA, and PTCT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PHMMF, XENE, KNSA, and PTCT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHMMF, XENE, KNSA, and PTCT Company Descriptions

Kiniksa Pharmaceuticals International NASDAQ:KNSA

Pharma Mar OTCMKTS:PHMMF

PTC Therapeutics NASDAQ:PTCT

Xenon Pharmaceuticals NASDAQ:XENE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PHMMF, XENE, KNSA, and PTCT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PHMMF, XENE, KNSA, and PTCT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PHMMF, XENE, KNSA, and PTCT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHMMF, XENE, KNSA, and PTCT Company Descriptions

Kiniksa Pharmaceuticals International NASDAQ:KNSA

Pharma Mar OTCMKTS:PHMMF

PTC Therapeutics NASDAQ:PTCT

Xenon Pharmaceuticals NASDAQ:XENE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools